-
Michael E. Stern
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Chris S. Schaumburg
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Karyn F. Siemasko
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Jianping Gao
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Larry A. Wheeler
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Devin A. Grupe
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Cintia S. De Paiva
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Virginia L. Calder
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Margarita Calonge
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Jerry Y. Niederkorn
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.
-
Stephen C. Pflugfelder
From 1Allergan, Inc., Biological Sciences, Inflammation Research Program, Irvine, California; 2Baylor College of Medicine, Ocular Surface Center, Cullen Eye Institute, Houston, Texas; 3Department of Ocular Biology and Therapeutics, University College London, Institute of Ophthalmology, London, United Kingdom; Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain; and Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, Texas.